Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a strong-buy rating in a research report report published on Saturday morning.

REGN has been the topic of a number of other research reports. Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Morgan Stanley raised their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Royal Bank Of Canada boosted their target price on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Finally, Leerink Partners reiterated a “market perform” rating and set a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $801.70.

Regeneron Pharmaceuticals Price Performance

REGN opened at $805.93 on Friday. Regeneron Pharmaceuticals has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The firm has a 50-day moving average of $679.69 and a 200 day moving average of $714.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The firm has a market cap of $82.98 billion, a P/E ratio of 19.92, a PEG ratio of 1.37 and a beta of 0.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $12.81 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock valued at $1,090,030 over the last three months. Company insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $5,682,636,000. Vanguard Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after purchasing an additional 26,884 shares during the period. Dodge & Cox boosted its holdings in Regeneron Pharmaceuticals by 1.0% in the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after purchasing an additional 45,513 shares during the period. Franklin Resources Inc. grew its position in shares of Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after purchasing an additional 106,861 shares in the last quarter. Finally, Nuveen LLC grew its position in shares of Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after purchasing an additional 835,240 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.